Milford MA. – Prestige Scientific is excited to announce the successful completion of a Vice President, Medical Affairs for an organization advancing the development of investigational tissue-based biologic therapies for multiple ultra-rare diseases. The company’s lead compound has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation.
This is a very important hire for our client. Michael Barros, Managing Partner of Prestige Scientific added, “Finding the right candidate had its challenges. Many searches at this level do but our result is a proven executive that can think strategically regarding how to best position the organizations communications to allow Physicians to correctly diagnosis the targeted disease and get an available therapy to these patients.
”The company’s CEO stated, “We are very excited! Appreciate the hard work and effort from you and your team to help make this happen.”
Client: Biopharmaceutical Company focused on developing innovative treatments for patients with rare diseases. Our client has has initiated a rolling BLA submission with the FDA for its lead compound. They are simultaneously preparing to initiate a clinical trial of an investigational enzyme replacement therapy for the treatment an additional rare disease.
About Prestige Scientific:
Prestige Scientific is an executive search firm that advises our clients on recruiting impactful leaders. We provide our clients with a performance-based hiring system that identifies leaders with past success meeting similar corporate objectives as their own, while overcoming challenges and adhering to critical timelines. We have dedicated experts in eleven practice areas that mirror a typical biopharma company, allowing us to support our client's growth from Discovery through Commercial.
